InVivo Therapeutics engages the FDA to discuss the regulatory path for its injectable hydrogel for neurological pain, anticipating an annual market potential of $22 billion.
InVivo engages the FDA to move forward on injectable pain-relief hydrogen, aims for $22B yearly market [1]
InVivo Therapeutics [2] (OTC:NVIV [3]) is hoping to break into what may be a $22 billion annual market with its new combination injectable hydrogel for pain management in the lower back, legs, neck or arms.
Late last month, the company submitted a request to meet with the FDA's Office of Combination Products and the Center for Devices & Radiological Health to discuss the path for the product, a hydrogel engineered for sustained release of therapeutic molecules.
InVivo Therapeutics engages the FDA to discuss the regulatory path for its injectable hydrogel for neurological pain, anticipating an annual market potential of $22 billion. InVivo engages the FDA to move forward on injectable pain-relief hydrogen, aims for $22B yearly market News Well, 510(k), Food & Drug Administration (FDA), Pain Management, Regulatory/Complianceread more